ERIVEDGE
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
Nov 18, 2014 → Jul 15, 2020
NCT ID
NCT02667574About ERIVEDGE
ERIVEDGE is a phase 2 stage product being developed by Roche for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02667574. Target conditions include Basal Cell Carcinoma.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02667574 | Phase 2 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma